Fireside Chat Webinar
Fireside Chat Webinar
Hosted Live | 7 Feb 2023
Bob Proulx, Imagion’s CEO, and Dr. Yalia Jayalakshmi, Chief Development Officer discussed the latest positive independent review of our MagSense® HER2 imaging agent including what this means for Imagion Biosystems; how this accelerates our path to market; an update on the future of our technology; and fielded questions from attendees in a Q&A session.
Questions? Email us: investor@imagionbio.com
Interested to learn more information about our independent review and path to market?
Read More of Our Latest News
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
Imagion Biosystems to Present at Biotech Showcase 2024
MELBOURNE and SAN DIEGO — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announced that the
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
https://youtu.be/LI18OcgM9XM Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.